- Home
- PYPD vs SCLX Comparison
PYPD vs SCLX Comparison
Compare PYPD & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- SCLX
- Stock Information
- Founded
- PYPD 2008
- SCLX 2011
- Country
- PYPD Israel
- SCLX United States
- Employees
- PYPD N/A
- SCLX N/A
- Industry
- PYPD Medical/Dental Instruments
- SCLX Biotechnology: Pharmaceutical Preparations
- Sector
- PYPD Health Care
- SCLX Health Care
- Exchange
- PYPD Nasdaq
- SCLX Nasdaq
- Market Cap
- PYPD 34.8M
- SCLX 35.7M
- IPO Year
- PYPD 2020
- SCLX N/A
- Fundamental
- Price
- PYPD N/A
- SCLX $17.58
- Analyst Decision
- PYPD Strong Buy
- SCLX Strong Buy
- Analyst Count
- PYPD 5
- SCLX 3
- Target Price
- PYPD $12.00
- SCLX $367.50
- AVG Volume (30 Days)
- PYPD 49.5K
- SCLX 313.9K
- Earning Date
- PYPD 11-12-2025
- SCLX 08-13-2025
- Dividend Yield
- PYPD N/A
- SCLX N/A
- EPS Growth
- PYPD N/A
- SCLX N/A
- EPS
- PYPD N/A
- SCLX N/A
- Revenue
- PYPD N/A
- SCLX $44,236,000.00
- Revenue This Year
- PYPD N/A
- SCLX $89.26
- Revenue Next Year
- PYPD N/A
- SCLX $203.95
- P/E Ratio
- PYPD N/A
- SCLX N/A
- Revenue Growth
- PYPD N/A
- SCLX N/A
- 52 Week Low
- PYPD $2.30
- SCLX $3.60
- 52 Week High
- PYPD $3.93
- SCLX $39.90
- Technical
- Relative Strength Index (RSI)
- PYPD 45.84
- SCLX 42.76
- Support Level
- PYPD $3.34
- SCLX $14.80
- Resistance Level
- PYPD $3.57
- SCLX $19.41
- Average True Range (ATR)
- PYPD 0.13
- SCLX 3.44
- MACD
- PYPD -0.00
- SCLX -1.41
- Stochastic Oscillator
- PYPD 31.25
- SCLX 15.54
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.